Selected cases

Federal Court of Australia · [2025] FCA 1082

Watchlist

Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 2)

Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 2) [2025] FCA 1082 is a Federal Court interlocutory decision about the limits of a notice to produce in a patent revocation case. Virbac sought documents about other Abbey animal health projects involving Abbey's expert consultant, Dr Fadil Alawi. The Court held that the request lacked an apparent connection to the issues in the proceeding, was speculative and amounted to a fishing expedition. Compliance was dispensed with and Virbac was ordered to pay costs.

Federal Court of AustraliaNot recorded

These are plain-English explainers, not legal advice. They are a good starting point, but check the linked official source before you rely on a specific section, and get advice for your situation.

Talk to a lawyer

Decision snapshot

Facts

The dispute

Abbey Laboratories Pty Ltd brought Federal Court proceedings seeking revocation of Australian Patent Number 2012227241, which was held by Virbac (Australia) Pty Ltd. The patent concerned formulations for the topical treatment of cattle for parasites, and Abbey challenged it on novelty and lack of inventive step grounds. The priority date recorded in the judgment was 23 September 2011. In the revocation case, Abbey relied on expert evidence from Dr Fadil Alawi, described by the Court as a veterinary pharmaceutical formulator. Abbey had filed six expert reports from him. The first report was dated 21 August 2024 and served on 15 October 2024. In his first affidavit, Dr Alawi explained that since 2019 he had provided consulting services to animal health companies through Pharminnovation Ltd in relation to new product development and technology transfer. He said that his work included developing formulations for new products and reformulating existing products, reviewing literature and patent searches, conducting preliminary solubility studies, formulating prototypes and advising on stability trials. A key disclosure appeared in paragraph 18 of that affidavit. Dr Alawi said that since April 2019, Pharminnovation Ltd had been retained by Abbey to consult on approximately 5 to 9 projects relating to the development of animal health products, with the most recent project ending in June 2022. On 21 August 2025, less than two weeks before the hearing, Virbac served a notice to produce on Abbey. The notice sought documents for each of those 5 to 9 projects. It asked for sufficient documents to identify the active ingredients, excipients including solvents, method of administration and target animal for each project. It also sought documents recording the name of any registered animal health product resulting from a project. The Court specifically noted that the notice was not confined to projects involving formulations for the topical treatment of cattle for parasites. The period covered by the request was also eight to eleven years after the patent's priority date. Abbey responded by filing an interlocutory application dated 27 August 2025 seeking an order that compliance with the notice to produce be dispensed with. The Court therefore had to decide whether the notice had a proper forensic basis or whether it was an impermissibly speculative attempt to obtain broader commercial and technical material.

Issue

The legal question

The main issue was whether Virbac's notice to produce should be enforced in Abbey's patent revocation proceeding. The Court had to decide whether the documents sought about Abbey's other animal health product development projects with Pharminnovation had a legitimate forensic purpose and were apparently relevant in the sense used for subpoenas. That required more than a hope that useful material might emerge. The documents needed to plausibly relate to an issue in the proceeding, cast light on such an issue, or have a reasonable basis beyond speculation for likely adding to the relevant evidence. A secondary issue was whether the documents were needed to test the independence of Abbey's expert, Dr Alawi.

Outcome

Decision

The Federal Court ordered that compliance with the notice to produce dated 21 August 2025 be dispensed with and that Virbac pay Abbey's costs of the interlocutory application. Justice Jackman held that, on the evidence before the Court, he could not see how the requested documents plausibly related to any issue in the proceeding or would cast light on one. There was no reasonable basis for supposing the material would likely add to the relevant evidence, and it was speculative whether the documents would materially assist on any issue. The Court therefore regarded the notice as a fishing expedition. Although Abbey also argued orally that the notice should be set aside, the judge preferred to dispense with compliance rather than set it aside outright, because later evidence might potentially shed further light on the notice's legitimacy.

Practical impact

Commercial note

If your business receives a notice to produce, do not assume every request must be met without challenge. The party seeking documents needs to show a legitimate forensic purpose and more than speculation. In this case, the Court applied the same relevance concepts used for subpoenas and held that a broad request for documents about other projects did not have an apparent connection to the issues in the patent revocation case. The Court also drew an important procedural distinction between dispensing with compliance and setting aside the notice. Here, the judge chose to dispense with compliance rather than set the notice aside outright, leaving open the possibility that later evidence might change the position. For businesses, the practical message is to keep consultant engagements and project records organised, review whether a request is tied to a live issue, and act quickly if a broad or late notice seeks confidential technical material. If you are the party issuing the notice, draft it narrowly and be ready to explain exactly how the documents could assist on an identified issue.

The story

This judgment arose inside a larger patent revocation proceeding. Abbey Laboratories was seeking to revoke a patent owned by Virbac concerning formulations for the topical treatment of cattle for parasites. Abbey's pleaded grounds included novelty and lack of inventive step.

The immediate issue before the Court was much narrower. It was not a final ruling on patent validity. Instead, it was an interlocutory fight about whether Abbey had to comply with a notice to produce served by Virbac shortly before the hearing.

Abbey had relied on expert evidence from Dr Fadil Alawi, a veterinary pharmaceutical formulator. In his affidavit, Dr Alawi explained his consulting work through Pharminnovation Ltd and disclosed that Pharminnovation had been retained by Abbey on approximately 5 to 9 animal health product development projects since April 2019, with the most recent ending in June 2022.

Virbac then sought documents about each of those projects. The request was broad. It sought documents sufficient to identify active ingredients, excipients including solvents, method of administration and target animal, and also documents recording the name of any registered animal health product resulting from a project.

That request was important because it reached beyond the immediate patent subject matter. The Court specifically noted that the notice was not confined to projects involving formulations for the topical treatment of cattle for parasites. Abbey therefore applied for an order dispensing with compliance.

What documents were sought and why that mattered

The notice to produce was tied to paragraph 18 of Dr Alawi's affidavit, where he disclosed the existence of 5 to 9 Abbey projects handled by Pharminnovation. Virbac used that disclosure as the foundation for a request covering each of those projects.

The categories sought were commercially sensitive. They included the active ingredient or ingredients, excipients including solvents, method of administration and target animal for each project. If any project had resulted in the registration of an animal health product, Virbac also wanted documents recording the name of that registered product.

For a business, that is a significant level of detail. It can reveal product strategy, formulation choices, development pathways and market focus. In many technical disputes, those details may be among the most commercially valuable records a company holds.

The Court highlighted two features of the request. First, it was not limited to projects involving the same type of formulation as the patent in suit. Second, the projects fell in a period eight to eleven years after the patent's priority date, during which common general knowledge and Dr Alawi's own views and practices may well have changed.

Those features mattered because they weakened the apparent connection between the requested documents and the issues the Court had to decide in the revocation proceeding.

Quick checklist

0/5

What the Court decided

Justice Jackman held that, on the evidence currently before the Court, he was unable to see how the documents sought could plausibly be seen to relate to any issue in the proceedings or cast light on such an issue. He also said there was no reasonable basis for supposing that the material called for would likely add, in the end, in some way or another, to the relevant evidence in the case.

The judge described it as speculative whether the documents sought would materially assist on any issue in the proceedings. On that basis, he regarded the notice to produce as a fishing expedition.

The Court also rejected Virbac's argument about expert independence, at least on the material then available. Justice Jackman said he could not presently see that the requested documents were relevant to Dr Alawi's independence beyond the information already conveyed by paragraph 18 of the first affidavit. In the judge's view, that paragraph contained sufficient disclosure for any submission to be put on that topic at that stage.

The Court therefore ordered that compliance with the notice to produce dated 21 August 2025 be dispensed with. Virbac was ordered to pay Abbey's costs of the interlocutory application dated 27 August 2025.

The form of order is worth noting. Abbey's application sought an order dispensing with compliance, but in oral submissions Abbey also argued that the notice should be set aside. The judge preferred to dispense with compliance rather than set the notice aside outright. He explained that this was preferable against the possibility that evidence not currently before the Court might later throw further light on the legitimacy of the notice.

How businesses should read it

If your business is involved in patent litigation or any technical dispute, this case is a reminder that the other side cannot automatically use a notice to produce to obtain broad categories of internal project material. The Court will look for a real connection between the documents sought and the issues in the case.

That is especially important where the request reaches into unrelated projects, different products, different methods of administration or different target markets. The broader the request, the more clearly the issuing party may need to explain its forensic purpose.

The decision is also useful where an expert has disclosed prior consulting work with a party. Disclosure of that relationship may be enough for submissions about independence, without opening the door to production of all project records. That will depend on the circumstances, but this case shows that a court may resist attempts to turn a disclosed consulting relationship into a broad document trawl.

Timing is another practical point. The notice here was served less than two weeks before the hearing. The judgment does not say that lateness alone was decisive, but businesses should treat late-stage requests seriously because they can create immediate operational pressure. Collecting technical records, reviewing confidentiality issues and taking legal advice can be expensive and disruptive, particularly for smaller teams.

For businesses issuing notices to produce, the lesson is equally clear. Draft narrowly. Tie each category to a live issue in the pleadings, evidence or expert case. Be ready to explain why the documents could plausibly cast light on that issue. If you cannot do that, the request may fail and you may face a costs order.

Quick checklist

0/6

Practical steps for handling a notice to produce

When a notice to produce arrives, businesses should start with the issues in the proceeding, not with the document categories in isolation. Ask whether the request is directed to a pleaded issue, an identified evidentiary issue or a specific challenge to expert evidence. If the connection is unclear, that may be a warning sign.

Next, look at scope. A request that extends to multiple projects, products or time periods may be harder to justify than one focused on the product or conduct actually in dispute. In this case, the lack of confinement to topical cattle parasite formulations was a significant feature.

Then consider timing and burden. A notice served close to hearing can create practical prejudice even if the judgment does not treat lateness as a standalone ground. Businesses should assess how much work would be needed to identify, collect, review and potentially redact responsive documents.

Where expert independence is raised, compare the request against what has already been disclosed. The Court here considered the affidavit disclosure sufficient for submissions on independence at that stage. That does not mean further material can never be sought, but it does mean the issuing party needs a proper basis for going further.

Finally, keep records in a way that allows you to respond efficiently. Clear consultant engagement terms, project descriptions, dates and document management practices can reduce cost and help your legal team assess whether a request is properly targeted or should be resisted.

Dates and status

The judgment was delivered by Jackman J on 2 September 2025 in the General Division of the Federal Court of Australia, New South Wales Registry. It was delivered ex tempore and revised from transcript.

The ruling concerns an interlocutory application dated 27 August 2025 about a notice to produce dated 21 August 2025. It should not be read as deciding the underlying patent revocation proceeding.

How Sprintlaw can help